Pfizer Remains Immune To Lipitor Attack In U.K.

Law360, New York (June 28, 2006, 12:00 AM EDT) -- Chalking up another win for Pfizer Inc., a British appellate court has upheld the primary patent behind blockbuster cholesterol drug Lipitor, thwarting Ranbaxy Laboratories Ltd. yet again from launching a generic version of the drug.

On Wednesday, the U.K. appellate court affirmed an October High Court of Justice decision that found the basic patent on Lipitor, due to expire in November 2011, to be valid.

"We are pleased with the appellate court decision, which affirms the lower court ruling on our basic patent for Lipitor,” said...
To view the full article, register now.